anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemical technology, antibiotics. SUBSTANCE: phenoxymethylpenicillin is used in medicine and as an intermediate product for synthesis of semisynthetic β-lactam antibiotics. Method involves dissolving technical phenoxymethylpenicillin (basic substance content is about 60%) in butyl acetate containing 1-5 wt.-% acetic acid, separation of insoluble impurities from solution by filtration and isolation of the end product from the prepared solution. Method ensures to obtain concentrated butylacetate solution of phenoxymethylpenicillin. Yield of phenoxymethylpenicillin potassium salt is 89%, product activity is 1515 U/mg (theretical activity is 1530 U/mg). Phenoxymethylpenicillin can be obtained in the form of acid from the isolated potassium salt. EFFECT: high yield and quality of product, decreased butyl acetate consumption.
Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Systemic therapy with pembrolizumab and eftilagimod alpha and radiotherapy are administered concurrently. Systemic treatment lasts for 9 weeks (study week 1-9). Radiation therapy lasts for 5 weeks (5 days per week) in weeks 2-6. Surgery takes place 5-6 weeks after completion of radiation therapy (week 11-12). Any adjuvant treatment (chemotherapy, immunotherapy, radiation therapy) after surgical treatment is not allowed. Patients will be then followed up regularly for a period of 24 months.
Risk Summary

Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue lisinopril as soon as possible.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo/Fetal Risk:

Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly.

Fetal/Neonatal Adverse Reactions:

Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia and skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.

Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to lisinopril for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occur in neonates with a history of in utero exposure to lisinopril, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function.
Acute bronchiolitis is among the most common causes of hospitalizations in infants worldwide. Associations between weight and severity of respiratory syncytial virus (RSV) bronchiolitis remain unclear. The aim of this study was to evaluate this association. A single-center, retrospective cohort study of infants aged under 24 months, who were hospitalized between 2018 and 2022 for RSV bronchiolitis. Data from computerized medical records were extracted using the MDclone platform. Participants were divided into three groups according to weight percentiles: underweight (below 5th percentile), normal-weight, and overweight (above 85th percentile). A total of 1936 infants (mean age 6.3 months, 55% males) were included, comprising 274 infants who were underweight, 1470 with normal weight, and 192 with overweight. Underweight infants had a higher rate of admission to the pediatric intensive care unit (PICU) (9.1% vs. 3.5%, P < 0.005) and prolonged length of stay (LOS) in the hospital (3.13 vs. 2.79 days P < 0.001) compared to those with normal weight. Hyponatremia was also more common in the underweight group (23% vs. 15%, P < 0.001). A multivariable model accounting for prematurity and birthweight predicted a relative risk of 2.01 (95% CI 1.13-3.48, P = 0.015) for PICU admission and 1.42 (95% CI 1.17-1.7, P < 0.001) for a prolonged LOS. Being overweight was not associated with a more severe disease.  Conclusion: Underweight infants, hospitalized for RSV bronchiolitis, had a more severe disease course with a higher complication rate, including PICU admission and prolonged LOS. Thus, careful attention and supervision should be given to this subgroup of infants. What is Known: • Established risk factors for severe bronchiolitis include prematurity, BPD, CHD, and compromised immunity. • Abnormal weight status has been associated with an increased risk for morbidity and mortality from infectious diseases, proposedly due to the effects on endocrine and immunologic systems. What is New: • Underweight infants hospitalized with RSV bronchiolitis face an independent risk of PICU admission and prolonged hospital stay. • Conversely, overweight infants did not display associations with severity measures in our study.
The invention relates to a Chinese medicament for relieving smoke toxicity and smoke drunk, which is prepared from 10g of earthworm, 10g of thinleaf milkwort rootbark, 30g of heartleaf houttuynia herb and 10g of liquorice, wherein the accuracy of medicament proportions is between +5% and -5%. The method for taking the Chinese medicament comprises the following steps of: mixing the drugs; immersing in a medicinal pot with 600g of clear water for 1 hour; boiling with strong fire, and decocting with slow fire until 300 grams of decoction is reserved; and taking the decoction one dose per day at normal temperature. The medicament is taken one hour later after every dinner, and smoke toxicity can be cured by taking three doses as a course of treatment. Smoke drunk can be cured by taking one dose. The clinical application proves that: in 1 to 3 courses of treatment of a patient, the Chinese medicament for relieving smoke toxicity and smoke drunk can relieve symptoms during medicament taking, and can completely cure smoke toxicity and smoke drunk after taking. The Chinese medicament has the advantages of remarkable effect, no toxic or side effect, no dependence and low price.
The present invention relates generally to assessing abnormal patterns associated with disease from x-ray images, and in particular to assessing abnormal patterns associated with COVID-19 (new coronavirus pneumonia) from x-ray images using a machine learning network trained based on DRRs (digitally reconstructed radiographs) and ground truth derived from CT (computed tomography). Systems and methods for assessing disease are provided. An input medical image of a first modality is received. The lungs are segmented from the input medical image using a trained lung segmentation network, and the abnormal patterns associated with the disease are segmented from the input medical image using a trained abnormal pattern segmentation network. The trained lung segmentation network and the trained abnormal pattern segmentation network are trained based on 1) a composite image of the first modality generated from a training image of the second modality and 2) a target segmentation mask for the composite image generated from a training segmentation mask for the training image. An assessment of disease is determined based on the segmented lungs and the segmented abnormal pattern.
Described herein is a method including providing a hair care composition in an aerosol dispenser, wherein the hair care composition includes from about 20% to about 45% of a surfactant system. The hair care composition also includes from about 3% to about 20% of 1,3,3,3-hydrofluoropropene foaming agent. The hair care composition has a formula pressure of from about 43 psig to about 65 psig at 20°C and is dispensed as a foam via the aerosol dispenser. The foam has a density of from about 0.09 g/cm3 to about 0.20 g/cm 3 . The foaming agent within the hair care composition has a % saturation pressure of from about 66% to about 100%. The method also includes dispensing the hair care composition as a foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.05 g/cm3 to about 0.35 g/cm 3 .
Cognitive deficits are the most important cause of long-term dysfunction in patients with Neurofibromatosis type 1 (NF1). Among the most frequently-occurring difficulties are problems with attention, working memory (WM), and executive functioning (EF). Remediation and interventions to improve those deficits have the potential to impact the quality of life and long-term prognosis in this population. Cognitive training (CT) programs have increasingly been used independently or in conjunction with pharmacotherapies in children with accidental or disease-related brain injury. CogmedRM is both the most well-researched and widely-used CT program for remediation of WM deficits. Results from numerous randomized, controlled trials conducted with a variety of pediatric and adult patient populations generally show that CogmedRM training is associated with robust gains in performance-based WM scores over the short term, with some variability in improvement across disease groups. A single arm pilot study of CogmedRM in a sample of children with NF1 conducted at Children's National Medical Center has shown that the approach is likely feasible and acceptable to families.

Because many children with NF1 are treated with stimulant medications, and there is biological evidence that both CT and Methylphenidate act on dopaminergic systems, the investigators are also interested in examining whether or not there is a synergistic effect between these widely available and safe interventions. Thus, the aim is to assess the efficacy of a home-based, computerized cognitive training (CT) program in a sample of 90 children aged 8-16 with NF1 and working memory difficulties. This study will be conducted over the span of four years. If the participant qualifies following baseline testing, he/she will be randomized to the intervention, CogmedRM, or the active control condition, MobyMax (an online reading program). The participant will have 5-9 weeks to complete the program and will have follow-up testing 2 weeks after finishing the program. If CT, either singly or in combination with stimulant medication, can be shown to be efficacious in a sample of NF1 pediatric patients at high risk for neurocognitive deficits, this intervention plan could be rapidly translated to clinical practice.
FIELD: medicine. SUBSTANCE: patient's state is estimated and homeopathic means are prescribed. Additionally tongue types are determined: with one or several cross wavy grooves, with central longitudinal groove or without these features. All patients with concussion symptoms or even symptom-free ones of tongue type 1 are prescribed for bellis perenis or ruta preparations. Symptom-free patients of tongue type 2 received arnica, and those of tongue type 3 - glonoin. EFFECT: higher efficiency and accuracy.
BACKGROUND: In recent years cognitive frailty has emerged as an important predictor of adverse health outcomes in older adults. Herein, we aimed to investigate the prevalence and associated factors of cognitive frailty in a population of community-dwelling older adults in Iran.
METHOD: This cross-sectional study was conducted as part of the second cycle of the Amirkola Health and Aging Project (AHAP). Physical frailty and cognitive impairment were evaluated using the FRAIL questionnaire and the mini-mental state examination (MMSE) respectively. Cognitive frailty was defined as co-existence of frailty and cognitive impairment without presence of dementia. Depression and disability were assessed using the Persian version of geriatric depression scale (GDS) and instrumental activities of daily living (IADL) questionnaire.
RESULTS: Overall 1775 individuals (47.1% female) with mean age of 69.7 ± 7.3 years were included in the final analysis. The prevalence of cognitive frailty was 12.0%. The prevalence of cognitive frailty among males and females was 4.3% and 20.7%, respectively. After adjusting for all possible confounders through binary logistic regression analysis, factors such as older age (OR 1.06, CI 1.03-1.09), female gender (OR 2.25, CI 1.42-3.57), illiteracy (OR 3.84, CI 2.03-8.29), more comorbidities (OR 1.21, CI 1.12-1.31), depression (OR 2.01, CI 1.40-2.86), and greater IADL disability (OR 1.68, CI 1.44-3.96), were independently and significantly associated with cognitive frailty.
CONCLUSION: In this population of Iranian older adults, prevalence of cognitive frailty was consistent with its estimated mean global prevalence. Age, gender, illiteracy, comorbidities, depression and IADL disability were associated with cognitive frailty. Further research is required to develop screening tools and prevention strategies.
The invention discloses an all natural body lotion. The all natural body lotion comprises, by weight, 66-73% of honey, 12-18% of royal jelly and 13-19% of queen bee's fetuses. The queen bee's fetuses are sterilized, ethanol with the concentration of 75% is added into the queen bee's fetuses, and then the queen bee's fetuses are subjected to crushed mixing. The all natural body lotion does not contain any chemical engineering raw material or additive, bee products serve as all raw materials, and the all natural body lotion is suitable for all people. Users can conveniently use the all natural nutrition skin care product every day, and the skin is improved. The all natural body lotion can eliminate facial darkness, deeply purify pores, eliminate blackheads, pimples, pox marks, weaken freckles and facial tinea and decrustation caused by seasonal variation and eliminate various allergies, is remarkable in antifreezing effect and resistant to aging, can shrink the pores, remove wrinkles and soften cutin, enables the skin to be naturally white, smooth and tender and can adjust acid base equilibrium of the skin, improve immunity of the skin, thoroughly improve the skin and moisten the skin.
Project 1: This project will work to understand why women are affected by pulmonary arterial hypertension (PAH) so much more often than men. This observation is true in heritable, idiopathic and associated forms of PAH. While males and females have some similar hormone levels, certain hormones exist at higher levels in each gender. For example, estrogen levels are much higher in females, and thus seemed the most sensible place to start looking for differences that may be affecting disease. In a small, early study of our heritable patients, we found differences in how patients break down estrogens as compared to healthy control subjects. Now, we want to confirm that what we found is true in a much larger group of patients that includes idiopathic and associated forms of PAH. We will also look to see if testosterone and other androgenic hormones are somehow protective for males. If the observation holds true in the larger group of patients, then we may try to "fix" the hormone imbalance in a mouse model of PAH with a drug therapy, and see if it helps improve the mouse pulmonary hypertension without bad side effects to the animals. If the animal drug studies work, then we may be able to try this drug in patients to see if it will work as a human treatment.

Project 2: Despite major advances in understanding PAH in recent decades, safe, effective and tolerable therapies remain elusive. The metabolic syndrome (central obesity, insulin resistance, high blood pressure and hyperlipidemia-fats in the blood) has been implicated in PAH. Treating the downstream consequences of insulin resistance in the pulmonary vasculature is a new approach to effective intervention against this highly mortal disease. This project will study the role of insulin resistance in pulmonary arterial hypertension and determine if therapies to treat insulin resistance will improve pulmonary arterial hypertension.

Project 3: In Project 3, we are working on the theory that PAH can be treated by fixing cell-cell junctions in blood vessels with a drug called recombinant ACE2(angiotensin converting enzyme 2). This is the only approach so far that has worked to reverse disease in mouse models of heritable PAH, but we need to better understand how it is working and make sure it has long term safety in animal models before starting human trials, hopefully within a few years. Definition: Cell-cell junctions-all of our organs and body structures are made from cells. Normally, these cells (think of a balloon filled with water) line up right next to each other so that the cell membranes touch each other. Materials can flow from one cell to the next. In PAH patients it is believed that the cells in the linings of the small arteries are not able to line up together as they should.
Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
FIELD: medicine. SUBSTANCE: desired product is prepared by reaction of oxide of hexavalent molybdenum with dihydrate of oxalic acid. The process is followed by substitution of ligand in thus prepared oxalate complex for D, L-b-phenyl-a-alanine. Thus obtained product has formula MoO 2 (C 9 H 10 NO 2 )•H 2 O, its yield being 82.5 %. Toxicity of desired product LD 50  is 2425 mg per 1 kg of body mass. EFFECT: improves quality of desired product. 4 dwg, 2 tbl
All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Renal or hepatic insufficiency may cause elevated blood levels of glipizide and the latter may also diminish gluconeogenic capacity, both of which increase the risk of serious hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency, are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.
The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.

The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxidase inhibitors.

Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).

Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
Individual counseling will be provided to the intervention group within the scope of the Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP), based on Denis's Breastfeeding Self-Efficacy theory and hypnobreastfeeding philosophy. EMÖZGEDAP, which will be applied to pregnant women and their family relatives, will consist of 5 sessions lasting 7.5 hours (2 sessions with the woman and her family relatives, two sessions with the woman alone, and one with her family relatives alone).
Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
Disclosed is a method of treating concussion or other brain trauma in humans or other mammals by administering an effective dose of a gallium compound or gallium complex to the injured human or other mammal. The gallium compound may comprise, e.g., gallium nitrate, a docosahexaenonic acid salt of gallium with one to three of the gallium ligands being from docosahexaenonic acid, or other gallium compound or complex or combinations thereof. The gallium compound or complex may be administered orally, by spray, intravenously, subcutaneously, transdermally, intramuscularly, mucoadhesively or through oral or nasal inhalation. A transdermal patch containing the gallium compound may be applied after onset of the concussion or other brain trauma to permit rapid delivery of the compound through the skin. The gallium compound is preferably administered in an amount sufficient to maintain steady state blood concentrations. A preferred dosing is about 0.5 to about 20.0 mg/kg/day of body weight.
Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.